Fusion proteins comprising an anti-CD40 antibody and cancer antigens
US10980869B2 · kind B2 · utility
0Cited by
46References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2017 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Jun 17, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.